Search

Your search keyword '"Novi, Giovanni"' showing total 151 results
Start Over Author "Novi, Giovanni"
151 results on '"Novi, Giovanni"'

3. Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS

Author

Cellerino, Maria, Cordano, Christian, Boffa, Giacomo, Bommarito, Giulia, Petracca, Maria, Sbragia, Elvira, Novi, Giovanni, Lapucci, Caterina, Capello, Elisabetta, Uccelli, Antonio, and Inglese, Matilde

Subjects
Biomedical and Clinical Sciences, Ophthalmology and Optometry, Neurosciences, Biomedical Imaging, Neurological, Adult, Aged, Aging, Cohort Studies, Disease Progression, Female, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Retinal Ganglion Cells, Retinal Photoreceptor Cell Inner Segment, Retrospective Studies, Tomography, Optical Coherence, Young Adult
Abstract

To investigate whether inner nuclear layer (INL) thickness as assessed with optical coherence tomography differs between patients with progressive MS (P-MS) according to age and disease activity. In this retrospective longitudinal analysis, differences in terms of peripapillary retinal nerve fiber layer (pRNFL), ganglion cell layer + inner plexiform layer (GCIPL), INL and T1/T2 lesion volumes (T1LV/T2LV) were assessed between 84 patients with P-MS and 36 sex- and age-matched healthy controls (HCs) and between patients stratified according to age (cut-off: 51 years) and evidence of clinical/MRI activity in the previous 12 months RESULTS: pRNFL and GCIPL thickness were significantly lower in patients with P-MS than in HCs (p = 0.003 and p < 0.0001, respectively). INL was significantly thicker in patients aged < 51 years compared to the older ones and HCs (38.2 vs 36.5 and 36.7 μm; p = 0.038 and p = 0.04, respectively) and in those who presented MRI activity (new T2/gadolinium-enhancing lesions) in the previous 12 months compared to the ones who did not and HCs (39.5 vs 36.4 and 36.7 μm; p = 0.003 and p = 0.008, respectively). Recent MRI activity was significantly predicted by greater INL thickness (Nagelkerke R2 0.36, p = 0.001). INL thickness was higher in younger patients with P-MS with recent MRI activity, a criterion used in previous studies to identify a specific subset of patients with P-MS who best responded to disease-modifying treatment. If this finding is confirmed, we suggest that INL thickness might be a useful tool in stratification of patients with P-MS for current and experimental treatment choice.

Published
2019

5. Ghost spasticity in multiple sclerosis

Author

Trompetto, Carlo, Currà, Antonio, Puce, Luca, Mori, Laura, Pallecchi, Ilaria, Gazzola, Paola, Fabbri, Sabrina, Uccelli, Antonio, Novi, Giovanni, Crisafulli, Oscar, Serrati, Carlo, and Marinelli, Lucio

Published
2020
Full Text
View/download PDF

6. Cell-based assays for the detection of MOG antibodies: a comparative study

Author

Gastaldi, Matteo, Scaranzin, Silvia, Jarius, Sven, Wildeman, Brigitte, Zardini, Elisabetta, Mallucci, Giulia, Rigoni, Eleonora, Vegezzi, Elisa, Foiadelli, Thomas, Savasta, Salvatore, Banfi, Paola, Versino, Maurizio, Benedetti, Luana, Novi, Giovanni, Mancardi, Margherita Maria, Giacomini, Thea, Annovazzi, Pietro, Baroncini, Damiano, Ferraro, Diana, Lampasona, Vito, Reindl, Markus, Waters, Patrick, and Franciotta, Diego

Published
2020
Full Text
View/download PDF

9. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders

Author

Novi, Giovanni, Bovis, Francesca, Capobianco, Marco, Frau, Jessica, Mataluni, Giorgia, Curti, Erica, Zuliani, Luigi, Cavalla, Paola, Brambilla, Laura, Annovazzi, Pietro, Repice, Anna Maria, Lanzillo, Roberta, Esposito, Sabrina, Benedetti, Luana, Maietta, Ilaria, Sica, Francesco, Buttari, Fabio, Malucchi, Simona, Fenu, Giuseppe, Landi, Doriana, Bosa, Chiara, Realmuto, Sabrina, Malentacchi, Maria, Granella, Franco, Signori, Alessio, Bonavita, Simona, Uccelli, Antonio, and Sormani, Maria Pia

Published
2019
Full Text
View/download PDF

10. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders

Author

Ringelstein, Marius, Ayzenberg, Ilya, Lindenblatt, Gero, Fischer, Katinka, Gahlen, Anna, Novi, Giovanni, Hayward-Könnecke, Helen, Schippling, Sven, Rommer, Paulus S., Kornek, Barbara, Zrzavy, Tobias, Biotti, Damien, Ciron, Jonathan, Audoin, Bertrand, Berthele, Achim, Giglhuber, Katrin, Zephir, Helene, Kümpfel, Tania, Berger, Robert, Röther, Joachim, Häußler, Vivien, Stellmann, Jan-Patrick, Whittam, Daniel, Jacob, Anu, Kraemer, Markus, Gueguen, Antoine, Deschamps, Romain, Bayas, Antonios, Hümmert, Martin W., Trebst, Corinna, Haarmann, Axel, Jarius, Sven, Wildemann, Brigitte, Grothe, Matthias, Siebert, Nadja, Ruprecht, Klemens, Paul, Friedemann, Collongues, Nicolas, Marignier, Romain, Levy, Michael, Karenfort, Michael, Deppe, Michael, Albrecht, Philipp, Hellwig, Kerstin, Gold, Ralf, Hartung, Hans-Peter, Meuth, Sven G., Kleiter, Ingo, and Aktas, Orhan

Published
2022
Full Text
View/download PDF

13. Clinical epidemiology of amyotrophic lateral sclerosis in Liguria, Italy: a ten year follow up study.

Author

Cabona, Corrado, Ferraro, Pilar Maria, Scialò, Carlo, Bandettini Di Poggio, Monica, Novi, Giovanni, Gemelli, Chiara, Vignolo, Manuela, Rao, Fabrizio, Capovilla, Marina, Marogna, Maura, Mandich, Paola, Origone, Paola, Schenone, Angelo, and Caponnetto, Claudia

Subjects
AMYOTROPHIC lateral sclerosis, CLINICAL epidemiology, FOLLOW-up studies (Medicine), PERCUTANEOUS endoscopic gastrostomy, DELAYED diagnosis
Abstract

This article presents an updated analysis of the LIGALS register, a prospective study conducted over a ten-year period (2009-2018) in Liguria, Italy, aimed at evaluating the incidence, prevalence, clinical presentation, and management of amyotrophic lateral sclerosis (ALS). We calculated the mean annual crude incidence rate of ALS, assessed the point prevalence of ALS on January 1, 2018, and analyzed demographic factors, clinical characteristics, and clinical management strategies. Data analysis included Cox regression analysis to identify predictors of survival. The mean annual crude incidence rate of ALS was 3.16/100,000 per year (CI 95%) while the point prevalence of ALS on January 1, 2018, was 9.31/100,000 population (CI 95%). Among the patients, 6.5% were familial ALS, while 93.5% were sporadic cases. Clinical management strategies, including percutaneous endoscopic gastrostomy (PEG) and noninvasive ventilation (NIV), were employed. The study observed a stable frequency of NIV initiation and PEG placement over time, with a growing trend toward earlier PEG positioning. The mean survival from symptom onset was 39 months, whereas from diagnosis, it was 26 months. Cox regression analysis identified several predictors of survival, including gender, age at onset and diagnosis, site of onset, diagnostic category, phenotype, and diagnostic delay. This comprehensive analysis provides valuable insights into the long-term trends in ALS epidemiology and clinical management in Liguria, Italy. It underscores the importance of continued research efforts in understanding and addressing the challenges posed by ALS, particularly in terms of early diagnosis and optimizing clinical interventions to improve patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Impact of treatment on cellular immunophenotype in MS: A cross-sectional study

Author

Cellerino, Maria, Ivaldi, Federico, Pardini, Matteo, Rotta, Gianluca, Vila, Gemma, Bäcker-Koduah, Priscilla, Berge, Tone, Laroni, Alice, Lapucci, Caterina, Novi, Giovanni, Boffa, Giacomo, Sbragia, Elvira, Palmeri, Serena, Asseyer, Susanna, Høgestøl, Einar, Campi, Cristina, Piana, Michele, Inglese, Matilde, Paul, Friedemann, Harbo, Hanne F., Villoslada, Pablo, Kerlero de Rosbo, Nicole, and Uccelli, Antonio

Published
2020
Full Text
View/download PDF

17. Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study

Author

Gastaldi, Matteo, Foiadelli, Thoma, Greco, Giacomo, Scaranzin, Silvia, Rigoni, Eleonora, Masciocchi, Stefano, Ferrari, Sergio, Mancinelli, Chiara, Brambilla, Laura, Mancardi, Margherita, Giacomini, Thea, Ferraro, Diana, Della Corte, Marida, Gallo, Antonio, Di Filippo, Massimiliano, Benedetti, Luana, Novi, Giovanni, Versino, Maurizio, Banfi, Paola, Iorio, Raffaele, Moiola, Lucia, Turco, Emanuela, Sartori, Stefano, Nosadini, Margherita, Ruggieri, Martino, Savasta, Salvatore, Colombo, Elena, Ballante, Elena, Jarius, Sven, Mariotto, Sara, Franciotta, Diego, Iorio, Raffaele (ORCID:0000-0002-6270-0956), Gastaldi, Matteo, Foiadelli, Thoma, Greco, Giacomo, Scaranzin, Silvia, Rigoni, Eleonora, Masciocchi, Stefano, Ferrari, Sergio, Mancinelli, Chiara, Brambilla, Laura, Mancardi, Margherita, Giacomini, Thea, Ferraro, Diana, Della Corte, Marida, Gallo, Antonio, Di Filippo, Massimiliano, Benedetti, Luana, Novi, Giovanni, Versino, Maurizio, Banfi, Paola, Iorio, Raffaele, Moiola, Lucia, Turco, Emanuela, Sartori, Stefano, Nosadini, Margherita, Ruggieri, Martino, Savasta, Salvatore, Colombo, Elena, Ballante, Elena, Jarius, Sven, Mariotto, Sara, Franciotta, Diego, and Iorio, Raffaele (ORCID:0000-0002-6270-0956)

Abstract

Background IgG antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) define a subset of associated disorders (myelin oligodendrocyte glycoprotein associated disorders (MOGAD)) that can have a relapsing course. However, information on relapse predictors is scarce. The utility of retesting MOG-IgG over time and measuring their titres is uncertain. We aimed to evaluate the clinical relevance of longitudinal MOG-IgG titre measurement to predict relapses in patients with MOGAD. Methods In this retrospective multicentre Italian cohort study, we recruited patients with MOGAD and available longitudinal samples (at least one >3 months after disease onset) and tested them with a live cell-based assay with endpoint titration (1:160 cut-off). Samples were classified as € attack' (within 30 days since a disease attack (n=59, 17%)) and € remission' (≥31 days after attack (n=295, 83%)). Results We included 102 patients with MOGAD (57% adult and 43% paediatric) with a total of 354 samples (83% from remission and 17% from attack). Median titres were higher during attacks (1:1280 vs 1:640, p=0.001). Median onset titres did not correlate with attack-related disability, age or relapses. Remission titres were higher in relapsing patients (p=0.02). When considering the first remission sample available for each patient, titres >1:2560 were predictors of relapsing course in survival (log rank, p<0.001) and multivariate analysis (p<0.001, HR: 10.9, 95% CI 3.4 to 35.2). MOG-IgG seroconversion to negative was associated with a 95% relapse incidence rate reduction (incidence rate ratio: 0.05, p<0.001). Conclusions Persistent MOG-IgG positivity and high remission titres are associated with an increased relapse risk. Longitudinal MOG-IgG titres could be useful to stratify patients to be treated with long term immunosuppression. © 2023 Authors. All rights reserved

Published
2023

18. Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study

Author

Gastaldi, Matteo, primary, Foiadelli, Thomas, additional, Greco, Giacomo, additional, Scaranzin, Silvia, additional, Rigoni, Eleonora, additional, Masciocchi, Stefano, additional, Ferrari, Sergio, additional, Mancinelli, Chiara, additional, Brambilla, Laura, additional, Mancardi, Margherita, additional, Giacomini, Thea, additional, Ferraro, Diana, additional, Della Corte, Marida, additional, Gallo, Antonio, additional, Di Filippo, Massimiliano, additional, Benedetti, Luana, additional, Novi, Giovanni, additional, Versino, Maurizio, additional, Banfi, Paola, additional, Iorio, Raffaele, additional, Moiola, Lucia, additional, Turco, Emanuela, additional, Sartori, Stefano, additional, Nosadini, Margherita, additional, Ruggieri, Martino, additional, Savasta, Salvatore, additional, Colombo, Elena, additional, Ballante, Elena, additional, Jarius, Sven, additional, Mariotto, Sara, additional, and Franciotta, Diego, additional

Published
2022
Full Text
View/download PDF

21. A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis

Author

Marini, Cecilia, Cistaro, Angelina, Campi, Cristina, Calvo, Andrea, Caponnetto, Claudia, Nobili, Flavio Mariano, Fania, Piercarlo, Beltrametti, Mauro C., Moglia, Cristina, Novi, Giovanni, Buschiazzo, Ambra, Perasso, Annalisa, Canosa, Antonio, Scialò, Carlo, Pomposelli, Elena, Massone, Anna Maria, Bagnara, Maria Caludia, Cammarosano, Stefania, Bruzzi, Paolo, Morbelli, Silvia, Sambuceti, Gianmario, Mancardi, Gianluigi, Piana, Michele, and Chiò, Adriano

Published
2016
Full Text
View/download PDF

23. Case Report: Post-COVID-19 Vaccine Recurrence of Guillain–Barré Syndrome Following an Antecedent Parainfectious COVID-19–Related GBS

Author

Bellucci, Margherita, primary, Germano, Francesco, additional, Grisanti, Stefano, additional, Castellano, Chiara, additional, Tazza, Francesco, additional, Mobilia, Emanuela Maria, additional, Visigalli, Davide, additional, Novi, Giovanni, additional, Massa, Federico, additional, Rossi, Silvia, additional, Durando, Paolo, additional, Cabona, Corrado, additional, Schenone, Angelo, additional, Franciotta, Diego, additional, and Benedetti, Luana, additional

Published
2022
Full Text
View/download PDF

26. Predictors of ocrelizumab effectiveness in patients with multiple sclerosis

Author

Cellerino, Maria, primary, Boffa, Giacomo, additional, Lapucci, Caterina, additional, Tazza, Francesco, additional, Sbragia, Elvira, additional, Mancuso, Elisabetta, additional, Bruschi, Nicolo, additional, Minguzzi, Simona, additional, Ivaldi, Federico, additional, Poire, Ilaria, additional, Laroni, Alice, additional, Mancardi, Gian Luigi, additional, Capello, Elisabetta, additional, Uccelli, Antonio, additional, Novi, Giovanni, additional, and Inglese, Matilde, additional

Published
2021
Full Text
View/download PDF

27. Ocrelizumab treatment in patients with progressive multiple sclerosis: a single-center real-world experience (2504)

Author

Cellerino, Maria, primary, Boffa, Giacomo, additional, Lapucci, Caterina, additional, Sbragia, Elvira, additional, Bruschi, Nicolo, additional, Mancuso, Elisabetta, additional, Tazza, Francesco, additional, Poire, Ilaria, additional, Laroni, Alice, additional, Capello, Elisabetta, additional, Uccelli, Antonio, additional, Novi, Giovanni, additional, and Inglese, Matilde, additional

Published
2021
Full Text
View/download PDF

28. Short-term evaluation of alemtuzumab to ocrelizumab switch in MS patients with disease activity after alemtuzumab: an Italian multicentric study (2695)

Author

Lapucci, Caterina, primary, Frau, Jessica, additional, Cocco, Eleonora, additional, Vercellino, Marco, additional, Cavalla, Paola, additional, Petracca, Maria, additional, Lanzillo, Roberta, additional, Grossi, Paola, additional, Ferrò, Maria Teresa, additional, Zaffaroni, Mauro, additional, Tazza, Francesco, additional, Novi, Giovanni, additional, Uccelli, Antonio, additional, and Inglese, Matilde, additional

Published
2021
Full Text
View/download PDF

29. Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies

Author

Perra, Daniela, primary, Bongianni, Matilde, additional, Novi, Giovanni, additional, Janes, Francesco, additional, Bessi, Valentina, additional, Capaldi, Stefano, additional, Sacchetto, Luca, additional, Tagliapietra, Matteo, additional, Schenone, Guido, additional, Morbelli, Silvia, additional, Fiorini, Michele, additional, Cattaruzza, Tatiana, additional, Mazzon, Giulia, additional, Orrù, Christina D, additional, Catalan, Mauro, additional, Polverino, Paola, additional, Bernardini, Andrea, additional, Pellitteri, Gaia, additional, Valente, Mariarosa, additional, Bertolotti, Claudio, additional, Nacmias, Benedetta, additional, Maggiore, Giandomenico, additional, Cavallaro, Tiziana, additional, Manganotti, Paolo, additional, Gigli, Gianluigi, additional, Monaco, Salvatore, additional, Nobili, Flavio, additional, and Zanusso, Gianluigi, additional

Published
2021
Full Text
View/download PDF

30. Relapsing meningitis and limbic encephalitis in anti-AQP4-Ab-associated neuromyelitis optica spectrum disorder.

Author

Novi, Giovanni, Sbragia, Elvira, Benedetti, Luana, Schenone, Angelo, Uccelli, Antonio, Magliozzi, Roberta, Del Sette, Massimo, Inglese, Matilde, and Laroni, Alice

Subjects
*NEUROMYELITIS optica, *MAGNETIC resonance imaging, *SPINAL nerves, *SPINAL cord, *WHITE matter (Nerve tissue), *CLINICAL pathology
Abstract

neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease mainly affecting optic nerves and the spinal cord. Due to the potentially irreversible tissue damage, prevention of relapses is of utmost importance.We describe the atypical clinical course and pathology results of a patient with anti-aquaporin-4 antibody (anti-AQP4-Ab)-associated NMOSD who developed aseptic meningitis followed by limbic-encephalitis-like presentation with extensive brain lesions upon treatment with rituximab and tocilizumab.The patient developed subacute cognitive decline with magnetic resonance imaging (MRI) evidence of extensive brain white matter lesions. In the hypothesis of an opportunistic brain infection, she underwent brain biopsy of the temporal pole. Pathology results revealed typical NMOSD findings with complement activation, supporting the hypothesis of an atypical presentation of anti-AQP-Ab-associated NMOSD. Accordingly, treatment with the complement-targeting drug eculizumab was started, leading to a dramatic clinical and MRI improvement.aseptic meningitis and limbic encephalitis could represent a rare phenotype of anti-AQP4-Ab-associated NMOSD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Tailoring B cell depletion therapy in MS according to memory B cell monitoring

Author

Novi, Giovanni, primary, Bovis, Francesca, additional, Fabbri, Sabrina, additional, Tazza, Francesco, additional, Gazzola, Paola, additional, Maietta, Ilaria, additional, Currò, Daniela, additional, Bruschi, Nicolò, additional, Roccatagliata, Luca, additional, Boffa, Giacomo, additional, Lapucci, Caterina, additional, Pesce, Giampaola, additional, Cellerino, Maria, additional, Solaro, Claudio, additional, Laroni, Alice, additional, Capello, Elisabetta, additional, Mancardi, Gianluigi, additional, Sormani, Mariapia, additional, Inglese, Matilde, additional, and Uccelli, Antonio, additional

Published
2020
Full Text
View/download PDF

34. TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients

Author

Scialò, Carlo, primary, Tran, Thanh Hoa, additional, Salzano, Giulia, additional, Novi, Giovanni, additional, Caponnetto, Claudia, additional, Chiò, Adriano, additional, Calvo, Andrea, additional, Canosa, Antonio, additional, Moda, Fabio, additional, Caroppo, Paola, additional, Silani, Vincenzo, additional, Ticozzi, Nicola, additional, Ratti, Antonia, additional, Borroni, Barbara, additional, Benussi, Luisa, additional, Ghidoni, Roberta, additional, Furlanis, Giovanni, additional, Manganotti, Paolo, additional, Senigagliesi, Beatrice, additional, Parisse, Pietro, additional, Brasselet, Romain, additional, Buratti, Emanuele, additional, and Legname, Giuseppe, additional

Published
2020
Full Text
View/download PDF

35. MSJ872889_supplemental_table – Supplemental material for Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

Author

Zecca, Chiara, Bovis, Francesca, Novi, Giovanni, Capobianco, Marco, Lanzillo, Roberta, Frau, Jessica, Repice, Anna Maria, Hakiki, Bahia, Realmuto, Sabrina, Bonavita, Simona, Curti, Erica, Brambilla, Laura, Mataluni, Giorgia, Cavalla, Paola, Sapio, Alessia Di, Signoriello, Elisabetta, Barone, Stefania, Maniscalco, Giorgia T, Maietta, Ilaria, Maraffi, Isabella, Boffa, Giacomo, Malucchi, Simona, Nozzolillo, Agostino, Coghe, Giancarlo, Mechi, Claudia, Salemi, Giuseppe, Gallo, Antonio, Sacco, Rosaria, Cellerino, Maria, Malentacchi, Maria, Angelis, Marcello De, Lorefice, Lorena, Magnani, Eliana, Prestipino, Elio, Sperli, Francesca, Morra, Vincenzo Brescia, Fenu, Giuseppe, Barilaro, Alessandro, Abbadessa, Gianmarco, Signori, Alessio, Granella, Franco, Amato, Maria Pia, Uccelli, Antonio, Gobbi, Claudio, and Sormani, Maria Pia

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, MSJ872889_supplemental_table for Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience by Chiara Zecca, Francesca Bovis, Giovanni Novi, Marco Capobianco, Roberta Lanzillo, Jessica Frau, Anna Maria Repice, Bahia Hakiki, Sabrina Realmuto, Simona Bonavita, Erica Curti, Laura Brambilla, Giorgia Mataluni, Paola Cavalla, Alessia Di Sapio, Elisabetta Signoriello, Stefania Barone, Giorgia T Maniscalco, Ilaria Maietta, Isabella Maraffi, Giacomo Boffa, Simona Malucchi, Agostino Nozzolillo, Giancarlo Coghe, Claudia Mechi, Giuseppe Salemi, Antonio Gallo, Rosaria Sacco, Maria Cellerino, Maria Malentacchi, Marcello De Angelis, Lorena Lorefice, Eliana Magnani, Elio Prestipino, Francesca Sperli, Vincenzo Brescia Morra, Giuseppe Fenu, Alessandro Barilaro, Gianmarco Abbadessa, Alessio Signori, Franco Granella, Maria Pia Amato, Antonio Uccelli, Claudio Gobbi and Maria Pia Sormani in Multiple Sclerosis Journal

Published
2019
Full Text
View/download PDF

36. Relationship Between Retinal Layer Thickness and Disability Worsening in Relapsing-Remitting and Progressive Multiple Sclerosis.

Author

Cellerino, Maria, Priano, Luca, Bruschi, Nicolò, Boffa, Giacomo, Petracca, Maria, Novi, Giovanni, Lapucci, Caterina, Sbragia, Elvira, Uccelli, Antonio, and Inglese, Matilde

Abstract

Background: Data regarding the predictive value of optical coherence tomography (OCT)-derived measures are lacking, especially in progressive multiple sclerosis (PMS). Accordingly, we aimed at investigating whether a single OCT assessment can predict a disability risk in both relapsing-remitting MS (RRMS) and PMS. Methods: One hundred one patients with RRMS and 79 patients with PMS underwent Spectral-Domain OCT, including intraretinal layer segmentation. All patients had at least 1 Expanded Disability Status Scale (EDSS) measurement during the subsequent follow-up (FU). Differences in terms of OCT metrics and their association with FU disability were assessed by analysis of covariance and linear regression models, respectively. Results: The median FU was 2 years (range 1-5.5 years). The baseline peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell + inner plexiform layer (GCIPL) were thinner in PMS compared with RRMS (P = 0.02 and P = 0.003, respectively). In the RRMS population, multivariable models showed that the GCIPL significantly correlated with FU disability (0.04 increase in the EDSS for each 1-µm decrease in the baseline GCIPL, 95% confidence interval: 0.0060.08; P = 0.02). The baseline GCIPL was thinner in patients with RRMS with FU-EDSS >4 compared with those with FU-EDSS ≤4, and individuals in the highest baseline GCIPL tertile had a significantly lower FU-EDSS score than those in the middle and lowest tertile (P = 0.01 and P = 0.001, respectively). These findings were not confirmed in analyses restricted to patients with PMS. Conclusions: Among OCT-derived metrics, GCIPL thickness had the strongest association with short-medium term dis-ability in patients with RRMS. The predictive value of OCT metrics in the longer term will have to be further investi-gated, especially in PMS. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

37. Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

Author

Zecca, Chiara, primary, Bovis, Francesca, additional, Novi, Giovanni, additional, Capobianco, Marco, additional, Lanzillo, Roberta, additional, Frau, Jessica, additional, Repice, Anna Maria, additional, Hakiki, Bahia, additional, Realmuto, Sabrina, additional, Bonavita, Simona, additional, Curti, Erica, additional, Brambilla, Laura, additional, Mataluni, Giorgia, additional, Cavalla, Paola, additional, Di Sapio, Alessia, additional, Signoriello, Elisabetta, additional, Barone, Stefania, additional, Maniscalco, Giorgia T, additional, Maietta, Ilaria, additional, Maraffi, Isabella, additional, Boffa, Giacomo, additional, Malucchi, Simona, additional, Nozzolillo, Agostino, additional, Coghe, Giancarlo, additional, Mechi, Claudia, additional, Salemi, Giuseppe, additional, Gallo, Antonio, additional, Sacco, Rosaria, additional, Cellerino, Maria, additional, Malentacchi, Maria, additional, De Angelis, Marcello, additional, Lorefice, Lorena, additional, Magnani, Eliana, additional, Prestipino, Elio, additional, Sperli, Francesca, additional, Brescia Morra, Vincenzo, additional, Fenu, Giuseppe, additional, Barilaro, Alessandro, additional, Abbadessa, Gianmarco, additional, Signori, Alessio, additional, Granella, Franco, additional, Amato, Maria Pia, additional, Uccelli, Antonio, additional, Gobbi, Claudio, additional, and Sormani, Maria Pia, additional

Published
2019
Full Text
View/download PDF

40. Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience.

Author

Zecca, Chiara, Bovis, Francesca, Novi, Giovanni, Capobianco, Marco, Lanzillo, Roberta, Frau, Jessica, Repice, Anna Maria, Hakiki, Bahia, Realmuto, Sabrina, Bonavita, Simona, Curti, Erica, Brambilla, Laura, Mataluni, Giorgia, Cavalla, Paola, Di Sapio, Alessia, Signoriello, Elisabetta, Barone, Stefania, Maniscalco, Giorgia T, Maietta, Ilaria, and Maraffi, Isabella

Subjects
MULTIPLE sclerosis, B cells, MONOCLONAL antibodies, RITUXIMAB, JOHN Cunningham virus
Abstract

Background: Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS). Objective: To investigate the effectiveness and safety of rituximab in relapsing–remitting (RR) and progressive MS. Methods: This is a multicenter, retrospective study on consecutive MS patients treated off-label with rituximab in 22 Italian and 1 Swiss MS centers. Relapse rate, time to first relapse, Expanded Disability Status Scale (EDSS) progression, incidence of adverse events, and radiological outcomes from 2009 to 2019 were analyzed. Results: A total of 355/451 enrolled subjects had at least one follow-up visit and were included in the outcome analysis. Annualized relapse rate significantly decreases after rituximab initiation versus the pre-rituximab start year in RRMS (from 0.86 to 0.09, p <.0001) and in secondary-progressive (SP) MS (from 0.34 to 0.06, p <.0001) and had a slight decrease in primary-progressive (PP) MS patients (from 0.12 to 0.07, p = 0.45). After 3 years from rituximab start, the proportion of patients with a confirmed EDSS progression was 14.6% in the RRMS group, 24.7% in the SPMS group, and 41.5% in the PPMS group. No major safety concerns arose. Conclusion: Consistently with other observational studies, our data show effectiveness of rituximab in reducing disease activity in patients with MS. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

45. Analysis of the interferon gamma modulated pathways related to the therapeutic plasticity of bone marrow-derived mesenchymal stem cells through a SIIAC-based proteomic approach

Author

Lovato, Laura, Neri, Cristina, Marzano, Valeria, Novi, Giovanni, Mortera, Stefano Levi, Cavaliere, Chiara, Capriotti, Anna Laura, Pieroni, Luisa, De Rosbo, Nicole Kerlero, Urbani, Andrea, Uccelli, Antonio, Urbani, Andrea (ORCID:0000-0001-9168-3174), Lovato, Laura, Neri, Cristina, Marzano, Valeria, Novi, Giovanni, Mortera, Stefano Levi, Cavaliere, Chiara, Capriotti, Anna Laura, Pieroni, Luisa, De Rosbo, Nicole Kerlero, Urbani, Andrea, Uccelli, Antonio, and Urbani, Andrea (ORCID:0000-0001-9168-3174)

Abstract

no abstract avilable

Published
2014

47. Analysis of the interferon gamma modulated pathways related to the therapeutic plasticity of bone marrow-derived mesenchymal stem cells through a SILAC-based proteomic approach

Author

Lovato, Laura, primary, Neri, Cristina, additional, Marzano, Valeria, additional, Novi, Giovanni, additional, Mortera, Stefano Levi, additional, Cavaliere, Chiara, additional, Capriotti, Anna Laura, additional, Pieroni, Luisa, additional, De Rosbo, Nicole Kerlero, additional, Urbani, Andrea, additional, and Uccelli, Antonio, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results